Plasma and synovial concentrations of carprofen in dogs with chronic osteoarthritis

Summary

The objective of this study was to measure the synovial and plasma concentration of carprofen in normal and osteoarthritic stifle joints throughout a 12-hour period. Eight healthy male mixed breed hound dogs with chronic right stifle osteoarthritis (OA) secondary to right cruciate ligament transection, were used. Each dog was treated with carprofen (2mg/kg every 12 hours) for 14 days at four different time periods. Prior to treatment, each dog had baseline data collected that included two force plate evaluations (seven days apart), synovial fluid, and plasma collections. Plasma samples were collected at three hours post drug administration on days two, four, six, eight, 10, and 12. On days #7 and 14 plasma, serum, bilateral stifle synovial fluid and ground reaction forces (GRFs) were collected at three, six, nine, or 12 hours post-medication, depending upon the test protocol. Vertical and cranio-caudal ground reaction forces were recorded at each time period. Plasma concentrations measured at three hours remained constant over each testing protocol. There were not any differences between the plasma carprofen concentrations at three, nine, or 12 hours between days #7 or 14. A significant difference was not found in the carprofen synovial concentrations between left and right stifles at any time. Significant increases in vertical impulse data were found at six hours post-treatment, for all of the collection periods on days three, seven and 14. During the study, there was not any indication that carprofen had a ‘preference’ for the OA stifle as opposed to the normal stifle. Carprofen administration increased the total force transmitted through the abnormal limb.

Carprofen concentrations in the plasma and synovial fluid and ground reaction forces were measured in dogs with single stifle osteoarthritis at three, six, nine and 12 hours following dosing at 2 mg/kg every 12 hours. Carprofen did not have a ‘preference’ for the OA stifle as opposed to the normal stifle. Carprofen administration increased the total force transmitted through the abnormal limb.

Keywords

Plasma - synovial fluid - carprofen - osteoarthritis

• REFERENCES

• 1 Armstrong S, Lees P. Effects of R and S enantiomers and a racemic mixture of carprofen on the production and release of proteoglycan and prostaglandin E2 from equine chondrocytes and cartilage explants. Am J Vet Res 1999; 60: 98-104.
• 2 Benton HP, Vasseur PB. et al. Effect of carprofen on sulfated glycosaminoglycan metabolism, protein synthesis, and prostaglandin release by cultured osteoarthritic canine chondrocytes. Am J Vet Res 1997; 58: 286-92.
• 3 Budsberg SC, Evens DJ, Brown J. et al. Evaluation of limb symmetry indices using ground reaction forces in healthy dogs. Am J Vet Res 1993; 54: 1569-74.
• 4 Budsberg SC, Johnston SA, Schwarz PD, DeCamp CE, Claxton R. Efficacy of etodolac for the treatment of osteoarthritis of the hip joints in dogs. J Am Vet Med Assoc 1999; 214: 1-5.
• 5 Budsberg SC, Jevens DJ, Brown J. et al. Evaluation of limb symmetry indices by ground reactions forces in healthy dogs. Am J Vet Res 1993; 54: 1569-74.
• 6 Budsberg SC. Outcome assessment in clinical trials involving medical management of osteoarthritis in small animals. Vet Clin North Am 1997; 27: 815-23.
• 7 Campbell WG. Synovialfine structure and permeability after intra-articular nitrogen mustard. Arch Path 1968; 83: 162-74.
• 8 Christensen SB, Reimann I, Henriksen O. et al. Experimental osteoarthritis in the rabbit: a study of Xenon-133 washout rates from the synovial cavity. Acta Ortho Scand 1982; 53: 167-74.
• 9 Dittrich P. et al. Pharmacokinetics of indomethacin i.m. in blood, synovial fluid, synovial membrane, muscle, fat, bone, and spinal fluid. Eur J Rheumatol Inflamm 1984; 07: 45-50.
• 10 Famaey JP. Correlation of NSAID plasma levels and therapeutic response. Clin Rheumatol 1985; 04: 124-132.
• 11 Farr M, Willis JV. Investigation of phenylbutazone in synovial fluid. J Intern Med Res (Suppl) 1977; 05: 26-9.
• 12 Fox SM, Campbell S. Update: Two years (1997-1998) clinical experience with Rimadyl^® (carprofen). Technical Bulletin. August 1999
• 13 Fox SM, Johnston SA. Use of carprofen for the treatment of pain and inflammation in dogs. J Am Vet Med Assoc 1997; 210: 1493-8.
• 14 Friedman LM, Furberg CD, DeMets DL. Fundamentals of clinical trials. 3rd ed. St Louis: CV Mosby Co; 1996
• 15 Gaucher A. et al. Diffusion of oxyphenbutazone into synovial fluid, synovial tissue, joint cartilage and cerebrospinal fluid. Eur J Clin Pharmacol 1983; 25: 107-12.
• 16 Holtsinger RH, Parker RB, Beale BS. et al. The therapeutic efficacy of carprofen in 209 clinical cases of canine degenerative joint disease. Vet Comp Orthop Traumat 1992; 05: 140-4.
• 17 Jenkins CC, Kanara EW. First-year clinical experience with Rimadyl^® (carprofen): Assessment of product safety. Technical Bulletin. May 1998
• 18 Jevens DJ, Hauptman JG, DeCamp CE. et al. Contributions to variance in force plate analysis of gait in dogs. Am J Vet Res 1993; 54: 612-5.
• 19 Lascelles BDX, Cripps PJ, Jones A. et al. Efficacy and kinetics of carprofen administered preoperatively or postoperatively for the prevention of pain in dogs undergoing ovariohysterectomy. Vet Surg 1998; 27: 568-682.
• 20 Lin JH, Cocchetto DM, Duggan DE. Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs. Clin Pharm 1987; 12: 402-32.
• 21 MacPhail CM, Lappin MR, Meyer DJ. et al. Hepatocellular toxicosis associated with administration of carprofen in 21 dogs. J Am Vet Med Assoc 1998; 212: 1895-901.
• 22 McKellar QA, Delatour P, Lees P. Stereo-specific pharmacodynamic and pharmacokinetics of carprofen in the dog. J Vet Pharmacol Therap 1994; 17: 447-54.
• 23 McKellar QA, Pearson T, Gogan JA. et al. Pharmacokinetics, tolerance and serum thromboxane inhibition of carprofen in the dog. J Small Anim Pract 1990; 31: 443-8.
• 24 Owens JG, Kamerling SG, Barker SA. Pharmacokinetics of ketoprofen in healthy horses and horses with acute synovitis. J Vet Pharmacol Ther 1995; 18: 187-95.
• 25 Ray JE, Wade DN, Graham GG. et al. Pharmacokinetics of carprofen in plasma and synovial fluid. J Clin Pharm 1979; 19: 635-43.
• 26 Ricketts AP, Lundy KM, Seibel SB. Evaluation of selective inhibition of canine cyclooxygenase 1 and 2 by carprofen and other non-steroidal anti-inflammatory drugs. Am J Vet Res 1998; 59: 1441-6.
• 27 Simkin PA. Concentration-effect relationships of NSAIDs. J Rheumatol (Suppl) 1988; 17: 40-3.
• 28 Stewart CF. et al. Influence of concomitant aspirin or prednisone on methotrexate synovial fluid concentrations. J Pharmacol Exp Ther 1987; 243: 131-7.
• 29 Vasseur PB, Johnson AL, Budsberg SC. et al. Randomized, controlled trial of the efficacy of carprofen, a non-steroidal antiinflammatory drug, in the treatment of osteoarthritis in dogs. J Am Vet Med Assoc 1995; 206: 807-11.